|
1.
|
|
12 p, 600.5 KB |
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
/
Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ;
Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Araújo, Luis (Universitário de Coimbra) ;
Casasnovas, Olivier (CHU Dijon Bourgogne) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Yeh, Su-Peng (China Medical University Hospital) ;
Bouabdallah, Krimo (University Hospital of Bordeaux) ;
Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ;
Kim, Won Seog (Samsung Medical Center) ;
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ;
Koh, Youngil (Seoul National University Hospital) ;
Re, Alessandro (ASST Spedali Civili Brescia) ;
Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ;
Chamuleau, Martine (Vrije Universiteit Amsterdam) ;
Le Gouill, Steven (Institut Curie) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ;
van der Poel, Marjolein W. M. (Maastricht University Medical Center) ;
Abbadessa, Giovanni (Sanofi) ;
Meng, Robin (Sanofi) ;
Ji, Ran (Sanofi) ;
Lépine, Lucie (Sanofi) ;
Saleem, Rao (Sanofi) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 -  10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119
|
|
|
2.
|
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
|
3.
|
|
8 p, 132.9 KB |
Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting
/
Muntañola, Ana (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Arguiñano, José M (Hospital Universitario de Navarra) ;
Dávila, Julio (Complejo Asistencial de Ávila) ;
de Villambrosia, Sonia González (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Jiménez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Salar, Antonio (Universitat Pompeu Fabra)
Although rituximab is generally well-tolerated, infusion-related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low-speed infusion rates have been recommended. [...]
2022 - 10.1111/cts.13450
Clinical and Translational Science, Vol. 16 (november 2022) , p. 305-312
|
|
|
4.
|
|
14 p, 1.3 MB |
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)
/
Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ;
Karmali, Reem (Northwestern University Feinberg School of Medicine) ;
Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ;
Popat, Rakesh (University College London) ;
Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ;
Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ;
El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ;
Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ;
Radford, John (University of Manchester) ;
de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ;
Zinzani, Pier Luigi (Università di Bologna) ;
Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ;
Townsend, William (University College London Hospitals) ;
Miao, Harry (Takeda Development Center Americas) ;
Proscurshim, Igor (Takeda Development Center Americas) ;
Wang, Shining (Takeda Development Center Americas) ;
Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ;
Yuan, Ying (Takeda Development Center Americas) ;
Zhu, Jiaxi (Takeda Development Center Americas) ;
Stumpo, Kate (Takeda Development Center Americas) ;
Shou, Yaping (Takeda Development Center Americas) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70
|
|
|
5.
|
|
12 p, 927.8 KB |
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
/
Kwon, Mi (Hospital General Universitario Gregorio Marañón) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Reguera-Ortega, Juan Luis (Instituto de Biomedicina de Sevilla) ;
Corral, Lucía López (Instituto de Investigación Biomédica de Salamanca) ;
Morales, Rafael Hernani (Hospital Clínic Universitari (València)) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Domínguez, María Luisa Guerra (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Pina, Jose Maria Sanchez (Hospital Universitario 12 de Octubre (Madrid)) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Catala, Eva (Vall d'Hebron Institut d'Oncologia) ;
Delgado, Javier (Instituto de Biomedicina de Sevilla) ;
Henriquez, Hugo Luzardo (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ribera Santasusana, Jose Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Cebrián, Nuria Martínez (Hospital Clínic i Provincial de Barcelona) ;
Martin, Jose Luis Diez (Universidad Complutense de Madrid) ;
Martín, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. [...]
2022 - 10.3324/haematol.2022.280805
Haematologica, Vol. 108 (january 2023) , p. 110-121
|
|
|
6.
|
|
10 p, 2.2 MB |
ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation
/
Calpe, Eva (Hospital Universitari Vall d'Hebron) ;
Purroy i Zuriguel, Noèlia (Hospital Universitari Vall d'Hebron) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Carabia, Júlia (Hospital Universitari Vall d'Hebron) ;
Palacio-García, Carles (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
ZAP-70 in chronic lymphocytic leukemia (CLL) is associated with enhanced response to microenvironmental stimuli. We analyzed the functional consequences of ZAP-70 ectopic expression in malignant B-cells in a xenograft mouse model of disseminated B-cell leukemia. [...]
2013 - 10.1371/journal.pone.0081221
PloS one, Vol. 8 (december 2013)
|
|
|
7.
|
|
10 p, 3.1 MB |
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia
/
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Purroy i Zuriguel, Noèlia (Vall d'Hebron Institut d'Oncologia) ;
Calpe, Eva (Vall d'Hebron Institut d'Oncologia) ;
Palacio-García, Carles (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironment, being the BCR pathway one key player in this crosstalk. Among proteins participating, ZAP-70 enhances response to microenvironmental stimuli. [...]
2017 - 10.1038/s41598-017-12135-7
Scientific reports, Vol. 7 (september 2017)
|
|
|
8.
|
|
15 p, 1.2 MB |
First-in-Human Phase I Study of Iadademstat (ORY-1001) : A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
/
Salamero, Olga (Vall d'Hebron Institut d'Oncologia) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Willekens, Christophe (Institut Gustave Roussy (Villejuif, França)) ;
Pérez-Simón, José Antonio (Universidad de Sevilla) ;
Pigneux, Arnaud (Centre Hospitalier Universitaire CHU Bordeaux) ;
Récher, Christian (Hospitalier Universitaire de Toulouse) ;
Popat, Rakesh (University College London) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Molinero, César (Parc Científic de Barcelona. Oryzon Genomics) ;
Mascaró, Cristina (Parc Científic de Barcelona. Oryzon Genomics) ;
Vila, Joaquim (Parc Científic de Barcelona. Oryzon Genomics) ;
Arévalo, M. Isabel (Parc Científic de Barcelona. Oryzon Genomics) ;
Maes, Tamara (Parc Científic de Barcelona. Oryzon Genomics) ;
Buesa, Carlos (Parc Científic de Barcelona. Oryzon Genomics) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Somervaille, Tim (The University of Manchester) ;
Universitat Autònoma de Barcelona
This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. [...]
2020 - 10.1200/JCO.19.03250
Journal of Clinical Oncology, Vol. 38 (october 2020) , p. 4260-4273
|
|
|
9.
|
|
12 p, 823.0 KB |
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
/
Hodkinson, Brendan P. (Oncology Translational Research (Estats Units d'Amèrica)) ;
Schaffer, Michael (Oncology Translational Research (Estats Units d'Amèrica)) ;
Brody, Joshua D. (Icahn School of Medicine at Mount Sinai (Estats Units d'Amèrica)) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Ben-Yehuda, Dina (Hadassah-Hebrew University Medical Center) ;
Avivi, Irit (Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine) ;
Forslund, Ann (Bristol-Myers Squibb) ;
Özcan, Muhit (Ankara University School of Medicine) ;
Alvarez, John (Janssen Research & Development, Spring Housen (Estats Units d'Amèrica)) ;
Ceulemans, Rob (Translational Medicine, Janssen Research & Development) ;
Fourneau, Nele (Translational Medicine, Janssen Research & Development) ;
Younes, Anas (Memorial Sloan Kettering Cancer Center) ;
Balasubramanian, Sriram (Janssen Research & Development (Estats Units d'Amèrica)) ;
Universitat Autònoma de Barcelona
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). [...]
2020 - 10.1016/j.tranon.2020.100977
Translational Oncology, Vol. 14 (december 2020)
|
|
|
10.
|
|
9 p, 6.7 MB |
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
/
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ;
Mayor, Regina (Hospital Universitari Vall d'Hebron) ;
Raheja, Priyanka (Vall d'Hebron Institut d'Oncologia) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ;
Tazon-Vega, Barbara ;
Palacio-García, Carles (Vall d'Hebron Institut d'Oncologia) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Jimenez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Nieto Sáchica, Juan Camilo (Vall d'Hebron Institut d'Oncologia) ;
Montoro Gómez, Julia (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Ricarte, Francisco (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Simo, Marc (Hospital Universitari Vall d'Hebron) ;
Puigdefabregas, Lluis (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. [...]
2020 - 10.3324/haematol.2019.241208
Haematologica, Vol. 106 (february 2020) , p. 513-521
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
